Evidence map›Paper›PMID 39246472›Full record

ArticleACS omega2024

Binding Mechanisms and Therapeutic Activity of Heterocyclic Substituted Arylazothioformamide Ligands and Their Cu(I) Coordination Complexes.

Laxmi Tiwari, Caleb Leach, Ashley Williams, Brandon Lighter, Zachariah Heiden, Mark F Roll, James G Moberly, Kenneth A Cornell, Kristopher V Waynant

Abstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laxmi TiwariDepartment of Chemistry, University of Idaho, Moscow, Idaho 83844, United States.
Caleb LeachDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.
Ashley WilliamsDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.
Brandon LighterDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.
Zachariah HeidenDepartment of Chemistry, Washington State University, Pullman, Washington 99164, United States.ORCID https://orcid.org/0000-0002-7192-4441
Mark F RollDepartment of Mechanical Engineering, University of Idaho, Moscow, Idaho 83844, United States.ORCID https://orcid.org/0000-0003-4701-1922
James G MoberlyDepartment of Chemical and Biological Engineering, University of Idaho, Moscow, Idaho 83844, United States.ORCID https://orcid.org/0000-0003-0950-0952
Kenneth A CornellDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.
Kristopher V WaynantDepartment of Chemistry, University of Idaho, Moscow, Idaho 83844, United States.ORCID https://orcid.org/0000-0002-4096-5726

Funding

Women's health: interplay of maternal diet and key demographics on neurological health in the rural frontier and remote WestP20GM103408 · NIGMS · UNIVERSITY OF IDAHO · PI Carolyn Hovde Bohach · 2012 to 2026
$59.8M
VPS35 D620N inhibits autophagy through disrupted hyaluronic acid-CD44 signalingP20GM109095 · NIGMS · BOISE STATE UNIVERSITY · PI OXFORD, JULIA THOM · 2014 to 2023
$22.7M
Surveillance genome sequencing to detect SARS-CoV-2 virus variants in MontanaP20GM103546 · NIGMS · UNIVERSITY OF MONTANA · PI BOWLER, BRUCE E · 2012 to 2021
$19.2M
Optimizing Deep Brain Stimulation for Parkinson's Disease.P20GM148321 · NIGMS · BOISE STATE UNIVERSITY · PI Paul Henry Davis · 2023 to 2026
$10.2M
Surveillance genome sequencing to detect SARS-CoV-2 virus variants in MontanaP30GM140963 · NIGMS · UNIVERSITY OF MONTANA · PI BOWLER, BRUCE E · 2021 to 2025
$6.9M
Center of Biomedical Research Excellence in Matrix Biology Phase 3P30GM154497 · NIGMS · BOISE STATE UNIVERSITY · PI JULIA THOM OXFORD · 2024 to 2026
$4.2M
NIGMS NIH HHS P20 GM103408NIGMS NIH HHS P20 GM103546NIGMS NIH HHS P20 GM109095NIGMS NIH HHS P20 GM148321NIGMS NIH HHS P30 GM140963NIGMS NIH HHS P30 GM154497
6 · The paper itself

Abstract

Finding new sources of biologically active compounds for anticancer or antimicrobial therapies remains an active area of research. Azothioformamides (ATFs) with a 1,3 N=N-C=S heterodiene backbone are a new class of biologically active compounds that chelate metals (e.g., Cu) forming stable ATF metal coordination complexes. In this study, ATF ligands were prepared with pyrrolidine, piperidine,

Identifiers

PMID39246472
PMCPMC11375723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.